COMMUNIQUÉS West-GlobeNewswire

Innovation Pharmaceuticals Announces Database Lock for Phase 2b Trial of Oral Prurisol for Psoriasis

29/06/2018 - 16:00

BEVERLY, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces database lock for its Phase 2b clinical trial of [...]

RavenQuest Eyes Massive Micro Cultivation Market -- CFN Media

29/06/2018 - 15:00

SEATTLE, June 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article [...]

Newly Public, James E. Wagner Cultivation Moves Toward Cannabis Oils -- CFN Media

29/06/2018 - 15:00

SEATTLE, June 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing [...]

Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII

29/06/2018 - 15:00

NOVATO, Calif., June 29, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European [...]

Devonian Announces Grant of Options

29/06/2018 - 14:45

QUEBEC CITY, June 29, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. (" Devonian " or the " Corporation ") (TSX VENTURE:GSD) announces that the Board of Directors has approved the grant of options (the ‘‘Options [...]

Devonian annonce l’octroi d’options

29/06/2018 - 14:45

QUÉBEC, 29 juin 2018 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSX CROISSANCE:GSD) annonce que le conseil d'administration a approuvé l'octroi d'options (les «options») pour [...]

Emisphere Development Update

29/06/2018 - 14:30

ROSELAND, N.J., June 29, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trial, PIONEER 3, with oral semaglutide, a once-daily oral formulation of the long-acting GLP [...]

Alder BioPharmaceuticals® Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine

29/06/2018 - 14:30

- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly migraine days - 1 in 5 [...]

Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine

29/06/2018 - 14:30

- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab’s robust efficacy is further improved at one year following third and fourth quarterly infusions - [...]

AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency

29/06/2018 - 14:30

NEW YORK, June 29, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal [...]

Tauriga Sciences Inc. Completes Initial Purchase Order with Blink Charging Co. for 4 Level II Electric Vehicle Pedestal Charging Units

29/06/2018 - 14:25

NEW YORK, NY, June 29, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of proprietary [...]

Canada House Wellness Group Announces Issuance of Stock Options

29/06/2018 - 14:23

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, June 29, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE:CHV) (“ Canada House ” or the “ Company ”) is pleased [...]

Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe

29/06/2018 - 14:11

First CHMP opinion for a CAR-T cell therapy in two distinct indications - DLBCL in adults and B-cell ALL in children Marketing Authorization Application (MAA) based on landmark global CAR-T clinical trials ELIANA and [...]

Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering

29/06/2018 - 14:10

FRAMINGHAM, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“ Arch ” or the “ Company ”), a developer of innovative materials as hemostatic and wound care devices, today announced the [...]

The American Health Council Selects Sara Safder, MD to Board of Physicians

29/06/2018 - 14:00

NEW YORK, June 29, 2018 (GLOBE NEWSWIRE) -- Sara Safder, MD was recently selected to the American Health Council’s Board of Physicians for her outstanding contributions to the medical field. A radiologist at Lakeland [...]

BioSig Technologies to Present at the Emerging Medical Technologies Spotlight

29/06/2018 - 14:00

Santa Monica, CA, June 29, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to address an unmet [...]

Tetra Bio-Pharma’s Evidence-Based Business Model Confirmed

29/06/2018 - 14:00

Tetra Bio-Pharma provides extension to North Bud Farms ORLEANS, Ontario, June 29, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB: [...]

Samumed Announces Presentation of Clinical Data Analysis on SM04690 for Treatment of Knee Osteoarthritis at International Workshop on Osteoarthritis Imaging (IWOAI) 2018 Conference

29/06/2018 - 14:00

SAN DIEGO, June 29, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present an analysis of phase 2 clinical data on SM04690 for the treatment of knee osteoarthritis (OA) as a poster at the [...]

ContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights Offering

29/06/2018 - 14:00

EDISON, N.J., June 29, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) (“ContraVir” or the “Company”), a biopharmaceutical company focused on the development and commercialization of therapeutic [...]